Biopharma startup Kardigan closed a US$254 million Series B round led by T. Rowe Price and Fidelity, marking one of the year’s largest biotech financings. The company specializes in next-generation cardiovascular therapeutics using gene-targeting and protein-design platforms. Funds will accelerate late-stage clinical trials and regulatory submissions across North America and Europe. Investors said the raise underscores renewed institutional confidence in precision-medicine innovation despite broader venture funding slowdowns in healthcare. Kardigan expects pivotal-trial data readouts by mid-2026.